New strategies for the treatment of inflammatory bowel diseases
Xavier Roblin, William Dronne, Stéphane Paul, Émilie Del Tedesco · Clinical Investigation · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2013
Abstract
Anti-TNF therapy is the most important treatment for inflammatory bowel disease patients. However, primary nonresponders are frequent and clinical recurrence under maintenance therapy is reported in 40% of the treated patients. The aim of this article is to explain the most important targets for the future of treatments in inflammatory bowel disease and to report the results of these news drugs in clinical practice. Two Phase III studies clearly indicate the interest of golimumab and vedolizumab in induction and maintenance treatment for ulcerative colitis patients. Soon it will be possible to analyze the principal regulation defect in each patient to design a more personalized treatment.
Before this step, it is important first to try to optimize treatment and then to consider a switch to another drug.
Open the resolved locator · 10.4155/cli.13.26
Metadata licence: OpenAlex metadata (CC0)